Mycoplasma - contamination of cell cultures

The safety of biological products derived from animal cells is associated with the properties of the cells themselves or their components, as well as with the possible presence of contaminants of microbial and viral origin. The suitability of cell substrate for production of prophylactic preparations is often determined by the features of the production process, which allows to benefit/risk ratio of the product. One of the common contaminants of cell substrates are mycoplasmas, type Mollicutes. As distinguished from other microorganisms they don’t have cell membranes, and parasitize a wide range of animals and plants, on the surface or inside the cells. Some mycoplasma species of are potentially pathogenic to humans, they compete for nutrients with cells in vitro , cause chromosomal aberrations, interfere with normal cell metabolism. The detection of mycoplasma contamination in cell substrates when manufacturing prophylactic preparations is required by regulatory documents.

клеточные культуры, первичные клетки, диплоидные клеточные линии, перевиваемые линии клеток, контаминанты, микоплазмы, питательные среды, методы определения микоплазм, флуоресценция, полимеразная цепная реакция (ПЦР), cell cultures, primary cells, diploid cell lines, finite cell lines, contaminants, mycoplasmas, culture media, methods for detecting mycoplasmas, fluorescence polymerase chain reaction (PCR)

1. Annex 2. Recommendations to assure the quality, safety and efficacy of poliomyelitis vaccines (oral, live, attenuated). Replacement of Annex 1 of WHO Technical Report Series, № 904, and Addendum to Annex 1 of WHO Technical Report Series, № 910. In: WHO Expert Committee on Biological Standardization, WHO Technical Report Series, № 980 (63 report). WHO; 2014.

2. Oral Polio Vaccine 1, 2, 3 types of oral solution (FS. 3.3.1.0037.15). The State Pharmacopoeia of the Russian Federation. 13th ed. V. 3. P. 1110–25. Available from: http://193.232.7.120/feml/clinical_ref/pharmacopoeia_3/HTML/ #1110/z (in Russian).

3. Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks, 2013. WHO Technical Report Series, № 978, 79–187.

4. Rubella vaccine culture alive (FS. 3.3.1.0024.15). The State Pharmacopoeia of the Russian Federation. 13th ed. V. 3. P. 964–72. Available from: http://193.232.7.120/feml/clinical_ref/pharmacopoeia_3/HTML /#1110/z (in Russian).

5. Stepanova LG, Alekseev SB, Zgursky AA, Shalunova NV, et al. Isolation and characterization of a new strain of diploid cells from human fetal lung tissue. Tsitologiya 1986; 28(12): 1373–6 (in Russian).

6. Hayflick L. A brief history of cell substrates used for the preparation of human biologicals. Developmental Biology 2001, 106: 5–23.

7. Polio vaccines: WHO position paper. March, 2016. Weekly Epidemiol Rec. 2016; 91(12): 145–68.

8. Shalunova NV, Merkulov VA, Comratov AV, Petruchuk EM, Semenova IS, Volgin AR, Trusov GA. Requirements for cell cultures, used for manufacture and quality control of immunobiological medicines. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2013; (1): 28–32 (in Russian).

9. Kolokoltsova TD, Saburina IN, Kubatiev AA. Cultures of human and animal cells: isolation, culturing, cryopreservation and control. Patogenez 2015; 13(2): 50–65 (in Russian).

10. Carrier T, Donahue-Hjelle L, Strama MJ. Banking Parental Cells According to CGMP Guidelines. A Practical Approach to Developing Stable Cell Lines. BioProcess International December 2009: 20–25. Available from: http://www.thermofisher.com/content/dam/LifeTech/global/applied-sciences/pdfs/Bioproduction/BPI_banking-parental-cells.pdf

11. Genzel Y, Reichl U. Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines. 2009; 8(12): 1681–92.

12. Barrett PN, Mundt W, Kistner O, Howard MK. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 2009; 8(5): 607–18.

13. Barhaleva OA, Ladyzhenskaya IP, Vorobieva MS, Shalunova NV, Podchernyaeva DYa, Mikhailova GR, Horosheva TV, Barinsky IF. «Vitagerpavak» — first domestic vaccine on a continuous Vero cell line (B). Voprosy virusologii 2009; (5): 33–7 (in Russian).

14. Barile MF, Rottem S. Mycoplasmas in cell culture. In: Kahane I. and Adoni A. (eds). Rapid diagnosis of mycoplasmas. New York: Plenum Press; 1993. P. 155–193.

15. Requirements for continuous cell lines used for biologicals production. In: WHO Expert Committee on Biological Standardization. Thirty-sixth report. Geneva: World Health Organization; 1987 (WHO Technical Report Series, № 745), Annex 3. Viral safety evaluation of biotechnology products.

16. Requirements for the use of animal cells as in vitro substrates for the production of biologicals. In: WHO Expert Committee on Biological Standardization. Forty-seventh report. Geneva: World Health Organization; 1998 (WHO Technical Report Series, № 878). Annex 1. Viral safety evaluation of biotechnology products.

17. Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications U. S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. 2010.

18. Gradoboev VN, Borisevich IV, Potryvaeva NV, Lebedinskaya EV, Chernikova NK, Timankova GD. Development and study of the properties of the immunoglobulin against Lassa fever. Voprosy virusologii 1997; 42(4): 168–71 (in Russian).

19. Krasnyansky VP, Potryvaeva NV, Borisevich IV, Gradoboev VN, Pashanina TP, Pshenichnov VA. Experience of producing inactivated vaccines against Lassa fever. Voprosy virusologii 1993; (6): 276–9 (in Russian).

20. Firsova IV, Shatohina IV, Borisevich IV, Evseev AA, Maksimov VA, Pantyuhov VB, Hmelev AL. The use of guinea pigs to evaluate the efficacy of vaccines against Lassa fever. Voprosy virusologii 2003; 48(6): 43–5 (in Russian).

21. Borisevich IV, Potryvaeva NV, Melnikov SA, Evseev AA, Krasnyansky VP, Maksimov VA. Getting immunoglobulin Marburg virus through blood serum of horses. Voprosy virusologii 2008; 53(1): 39–41 (in Russian).

22. Razin S, Hayflick L. Time-line of significant contributions to mycoplasmology. Biologicals 2010; 38: 191–2.

23. Hayflick L, Stinebring WR. Intracellular growth of pleuropneumonia-like organisms ANATOMICAL RECORD. 1955; 121(2): 477–8.

24. Robinson LB, Wichelhausen RH, Roisman B. Contamination of cell cultures by pneumonia-like organisms. Science 1956; 124: 1147–8.

25. Drexler HG, Uphoff CC. Contamination of cell cultures Mycoplasma. The Encyclopedia of Cell Technology. New York: Wiley; 2000. P. 609–27.

26. Nikfarjam L, Farzaneh P. Prevention and Detection of Mycoplasma Contamination in Cell Culture. Cell J. 2012; 13(4): 203–212.

27. Ryan J, Mariano J. What are Mycoplasmas? Available from: http://www.bionique.com/files/whataremycoplasma.pdf.

28. Drexler HG, Uphoff CC. Contamination of cell cultures Mycoplasma. The Encyclopedia of Cell Technology. New York: Wiley; 2000. P. 609–27.

29. Diakonov LP, ed. Animal cells in culture (method and application in biotechnology). Moscow; 2009 (in Russian).

30. Shalunova NV, Petruchuk EM, Kornilova OG, et al. Evaluation of continuous cell cultures. Guideline. Moscow: Federal State Budgetary Institution «Tarasevich State Research Institute of Standardization and Control of Biological Medicines» of the Ministry of Health and Social Development of the Russian Federation; 2011 (in Russian).

31. Order of the Ministry of Industry and Trade of the Russian Federation on June 14, 2013 № 916 «On Approval of Rules of the organization of production and quality control of medicines» (in Russian).

32. Research of immunobiological drugs for the presence of mycoplasma. In: Guidelines for preclinical studies of drugs (immunobiological drugs). Part 2. Moscow; 2012. P. 118–20.

33. Mikhailova GR, Hizhnyakova TM, Podchernyaeva RYa. The use of antibiotics for the decontamination of cell cultures from mycoplasma. Veterinarnaya patologiya 2005; (1): 48–51 (in Russian).

34. 2015.2.6.7. Mycoplasmas. P. 178–83. European Pharmacopoeia 8.0. Strasbourg: Council of Europe; 2015.

35. Berdnikova ZE. Development and standardization of methods for detection of mycoplasma — contaminants medical biologicals. Cand. Biol. Sci [thesis]. Moscow; 1991 (in Russian).

36. Kuleshov KV, Galnbek TV. Methodical instructions on the identification and differentiation of specific microorganisms of the genus Mycoplasma in cell lines by polymerase chain reaction. Moscow; 2012 (in Russian).

37. Uryvaev LV, Ionova KS, Dedova AV, et al. Analysis of contamination of cell cultures pestivirus BVDV and mycoplasma. Voprosy virusologii 2012; 57(5): 15–21 (in Russian).

38. Kazemiha VM, Shokgroser AV, Frabestani MR, et al. PCR-based detection and eradication of mycoplasma infections from various mammalian cell lines: a local experience. Cytotechnology 2009; 61(3): 117–24.

39. Shahhosseiny MH, Hosseiny Z, Khoramkhorshid HR, Azari S, Shokrgozar MA. Rapid and sensitive detection of Mollicutes in cell culture by polymerase chain reaction. J Basic Microbiol. 2010; 50(2): 171–8.

40. Kazemiha VM, Amanzadeh A, Memarnejadian A, Azari S, Shokrgozar M A, Mahdian R, Bonakdar S. Sensitivity of biochemical test in comparison with other methods for the detection of mycoplasma contamination in human and animal cell lines stored in the National Cell Bank of Iran. Cytotechnology 2014; 66(5): 861–73.

41. David Fiorentini. Available from: http://www.bioind.com/page_14199.

42. Uphoff CC, Drexler HG. Detection of Mycoplasma contamination in cell cultures. Curr Protoc Mol Biol. 2014; 106: 28.4.1–28.4.14.

43. Volokhov DV, Graham LJ, Brorson KA, Chizhikov VE. Mycoplasma testing of cell substrates and biologics: Review of alternative non-microbiological techniques. Mol Cell Probes. 2011; 25(2–3): 69–77.

44. Testing for the presence of mycoplasma (OFS 1.7.2.0031.15). The State Pharmacopoeia of the Russian Federation. 13th ed. V. 2. P. 827–835. Available from: http://193.232.7.120/feml/clinical_ref/ pharmacopoeia_2/HTML /#827/z.